Investor Relations

RECENT FILINGS

For copies of our financial statements and other continuous disclosure filings, please see the Greenbrook TMS profile at SEDAR or EDGAR by clicking the links below.

 November 2, 2023 • Toronto, on

GREENBROOK TMS RAISES US$2.0 MILLION IN DEBT FINANCING

MARCH 29, 2023 • Toronto, on

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), announced today the Company’s potential delay in the filing of its annual report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”) beyond the prescribed filing deadline in Canada.

 MARCH 24, 2023 • Toronto, on

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), today announced that it has (i) completed a non-brokered private placement (the “Private Placement”) of common shares of the Company (the “Common Shares”) for aggregate gross proceeds of approximately US$6.25 million, and (ii) entered into amendments to its credit facility (the “Credit Facility”) with Madryn Asset Management, LP and affiliates thereof (“Madryn”), whereby Madryn has agreed to extend two additional tranches of debt financing to the Company in an aggregate principal amount of US$2.0 million (the “New Loan”).

About us

Operating through 183 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than one million TMS treatments to over 27,000 patients struggling with depression.